← Back to Screener
bioAffinity Technologies, Inc. Common Stock (BIAF)
Price$2.69
Favorite Metrics
Price vs S&P 500 (26W)-3.60%
Price vs S&P 500 (4W)-4.73%
Market Capitalization$12.87M
All Metrics
Book Value / Share (Quarterly)$1.62
P/TBV (Annual)0.81x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.09
Price vs S&P 500 (YTD)138.23%
Gross Margin (TTM)31.40%
Net Profit Margin (TTM)-241.96%
EPS (TTM)$-15.42
10-Day Avg Trading Volume0.68M
EPS Excl Extra (TTM)$-15.42
EPS (Annual)$-8.66
ROI (Annual)-184.15%
Gross Margin (Annual)31.40%
Cash / Share (Quarterly)$1.43
Revenue Growth QoQ (YoY)-27.85%
ROA (Last FY)-136.03%
Revenue Growth TTM (YoY)-34.18%
EBITD / Share (TTM)$-6.12
Operating Margin (TTM)-171.58%
Cash Flow / Share (Annual)$-2.09
P/B Ratio1.77x
P/B Ratio (Quarterly)0.73x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.17x
Net Interest Coverage (TTM)-2.88x
ROA (TTM)-181.80%
EPS Incl Extra (Annual)$-8.66
Current Ratio (Annual)2.60x
Quick Ratio (Quarterly)2.51x
3-Month Avg Trading Volume6.02M
52-Week Price Return-79.70%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.46
P/S Ratio (Annual)2.09x
Asset Turnover (Annual)0.56x
52-Week High$17.44
EPS Excl Extra (Annual)$-8.66
26-Week Price Return5.15%
Quick Ratio (Annual)2.51x
13-Week Price Return126.98%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)2.60x
Enterprise Value$7.235
Asset Turnover (TTM)0.75x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)104.16x
Pretax Margin (Annual)-241.25%
Cash / Share (Annual)$1.43
3-Month Return Std Dev292.63%
Net Income / Employee (TTM)$-0
ROE (Last FY)-204.87%
Net Interest Coverage (Annual)-2.81x
EPS Basic Excl Extra (Annual)$-8.66
Receivables Turnover (TTM)7.57x
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$-15.42
Receivables Turnover (Annual)7.57x
ROI (TTM)-165.75%
P/S Ratio (TTM)2.09x
Revenue / Share (Annual)$3.58
Tangible BV / Share (Annual)$1.46
Price vs S&P 500 (52W)-114.80%
Year-to-Date Return142.37%
5-Day Price Return-10.06%
EPS Normalized (Annual)$-8.66
ROA (5Y Avg)-174.96%
Net Profit Margin (Annual)-241.96%
Month-to-Date Return-25.33%
Cash Flow / Share (TTM)$-0.95
EBITD / Share (Annual)$-6.12
Operating Margin (Annual)-171.58%
LT Debt / Equity (Annual)0.01x
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-15.42
P/TBV (Quarterly)0.81x
P/B Ratio (Annual)0.73x
Inventory Turnover (TTM)104.16x
Pretax Margin (TTM)-241.25%
Book Value / Share (Annual)$1.62
Price vs S&P 500 (13W)124.12%
Beta-1.06x
Revenue / Share (TTM)$1.38
ROE (TTM)-184.72%
52-Week Low$0.69
Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
2.17
2.17
2.17
2.17
Industry Peers — R&D — Physical Sciences(10)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
BIAFbioAffinity Technologies, Inc. Common Stock | — | -184.72% | — | — | $2.69 |
IQVIQVIA Holdings Inc. | 22.06x | 22.28% | 7.50% | — | $176.76 |
INCYIncyte Genomics Inc | 15.00x | 29.15% | 14.03% | — | $96.92 |
MEDPMedpace Holdings, Inc. Common Stock | 32.96x | 118.82% | 22.27% | — | $528.44 |
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $185.54 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.95 |
NRCNational Research Corporation Common Stock (Delaware) | 35.35x | 58.51% | 0.61% | 3.55% | $18.18 |
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.55 |
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.86 |
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.29 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.13 |
About
bioAffinity Technologies Inc develops noninvasive diagnostic tests and targeted cancer therapeutics, with a focus on early-stage cancer detection. The company's lead product, CyPath Lung, is a proprietary noninvasive test for detecting early-stage lung cancer. Its technology platform addresses a significant clinical market need for improved cancer diagnosis and treatment options.